Patient Checklist: Questions Before Any Peptide / GLP-1 Path

Important disclaimers (please read first)

1. This is education only. It is not medical advice, not legal advice, not a diagnosis, and not a treatment plan for you.
2. We are not saying you are a candidate. Nothing here confirms that you are (or are not) a fit for any medicine, peptide, compound, or program. At Regen Therapy MD, a physician decides only after a proper consult.
3. Results vary. Nothing on this page promises any outcome, product quality, or result.
4. Brand FDA-approved products are not the same as compounded versions. An FDA-approved brand medicine and a compounded formulation are not equivalent or interchangeable.
5. Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.
6. This page is not a shopping guide. It does not endorse any pharmacy, telehealth brand, overseas seller, peptide vendor, or “research” storefront. It does not tell you what to buy.
7. No dosing or protocols. This page does not give doses, reconstitution steps, stacking plans, or “how to use” instructions for any product.
8. Licensure and shipping. Any telehealth or shipping, if offered, applies only where we are licensed. This page does not claim nationwide service.
9. How Regen frames next steps. A discovery call is a non-clinical chat to help you learn what you may be a candidate for—never that you are one.
10. Claims and sources. Regulatory statements lean on cited FDA pages. No made-up testimonials.

Why a checklist (instead of a product list)

Online ads move fast. Patient safety questions should move carefully.

Before any GLP-1, incretin, or peptide conversation goes further, FDA consumer education and compounding statements already give patients a useful frame: unapproved products are not the same as FDA-approved medicines; compounded drugs are not FDA-approved; and products labeled “for research purposes” or “not for human consumption” have been sold to consumers with dosing instructions—something FDA urges people not to purchase.

This checklist helps you prepare for a clinician visit. It is not a shopping list and not legal advice.

Source for the regulatory themes below: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

Quick glossary (plain language)

Part A — Identity & regulatory status (ask first)

Use these questions with a licensed clinician or licensed pharmacy—not with a social-media vendor:

1. Is this an FDA-approved finished drug product for a labeled use that fits my situation—or something else?
   FDA notes that unapproved versions of GLP-1 drugs (including semaglutide and tirzepatide) do not undergo FDA’s review for safety, effectiveness, and quality before they are marketed.

2. If it is compounded, do you clearly understand that compounded ≠ FDA-approved?
   FDA: “Compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”

3. Would an FDA-approved product meet the medical need?
   FDA recommends that compounded drugs should only be used when a patient’s medical needs cannot be met by an FDA-approved drug (or when the approved drug is not commercially available, per FDA’s framing on that page).

4. Is anyone implying the compounded product is “the same as” the brand FDA-approved drug?
   FDA telehealth red flags include companies that make claims such as the compounded drug is the same as an FDA-approved drug. Brand and compounded are not equivalent.

5. Is the offer a product labeled “for research” or “not for human consumption”?
   FDA has warned companies that illegally sold unapproved drugs with those labels and dosing instructions for human use, and urges consumers not to purchase them.

6. If a name like retatrutide is mentioned, has anyone explained FDA’s compounding statement?
   FDA states retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition as approved drug components.

Part B — Clinical fit (bring your history)

These belong in a clinician visit—not in a cart checkout:

7. Have my medical history, medications, allergies, and relevant labs been reviewed by a licensed clinician?
   FDA advises patients to obtain a prescription from their doctor and fill it at a state-licensed pharmacy, and to talk with their doctor about questions.

8. What contraindications, boxed warnings, and labeled risks apply to my personal history?
   This page does not list doses or full label text. Ask your clinician to review the actual prescribing information for any FDA-approved product under discussion.

9. What monitoring plan would apply if a therapy were ever considered appropriate for me?
   Ask about follow-up visits, labs, and when to call for adverse effects—without treating this blog as a protocol.

10. What happens if I stop?
    Published withdrawal literature (for example STEP 1 extension, PMID 35441470) reports substantial mean weight regain after discontinuation in study populations. That is education about evidence patterns—not a prediction of your result. Individual results vary.

11. Am I being told I “am a candidate” before a proper evaluation?
    At Regen Therapy MD, a discovery call is non-clinical and explores what you may be a candidate for. Candidacy is decided only after a physician consult.

Part C — Source, labeling & logistics red flags (FDA consumer themes)

FDA’s unapproved-GLP-1 page lists telehealth warning signs for consumers. Translate them into questions:

12. Is a licensed clinician screening me and writing a prescription before any medicine is provided?
    FDA lists as a red flag: companies that do not require a screening and prescription by a licensed doctor before providing medicine.

13. Is a licensed doctor available to answer questions after I receive medication?
    FDA lists lack of clinician access after receipt as a red flag.

14. Does the pharmacy named on the label actually exist—and did it actually prepare the product?
    FDA reports fraudulent compounded semaglutide and tirzepatide with false label information; in some cases pharmacies on labels do not exist or did not compound the product.

15. Does packaging arrive damaged, warm (for products that require refrigeration), or without instructions for use?
    FDA discusses improper storage during shipping and advises patients not to use injectable GLP-1 drugs that arrive warm or with insufficient refrigeration when cold-chain storage is required. FDA also lists broken/damaged packaging or missing instructions as consumer red flags.

16. Are deep discounts or “too good to be true” prices the main pitch?
    FDA lists deep discounts / prices that seem too good to be true among telehealth red flags.

17. If buying online, am I using resources meant for safer online pharmacy practices?
    FDA points consumers to its BeSafeRx campaign for resources to safely buy prescription medicines online, and urges purchase from state-licensed pharmacies.

18. Do I know how to report a problem?
    FDA encourages reporting adverse events or quality problems via MedWatch. That is a public-safety channel—not a substitute for emergency care.

Part D — Peptides beyond GLP-1 (stay precise)

“Peptide therapy” online can mean very different things. Before any path:

19. What exact substance is being discussed—and is it an FDA-approved drug, a compounded preparation under U.S. compounding law, an investigational agent, or an unapproved research chemical?
    Do not accept vague branding in place of a category.

20. Is anyone selling a product with research-only labeling plus human-use instructions?
    FDA urges consumers not to purchase those products; quality is unknown and they may be harmful.

21. Is this page (or any ad) promising to resolve conditions, assured fat loss, or “same as Ozempic/Mounjaro” for a non-approved product?
    Treat absolute promises as a reason to pause and ask a clinician. This checklist does not endorse any product.

One-page printable checklist

Before any GLP-1 / peptide path, I can answer:

• ☐ Product category clear: FDA-approved vs compounded vs research/unapproved
• ☐ I understand compounded ≠ FDA-approved
• ☐ No one claimed “same as” brand FDA-approved without qualification
• ☐ Not buying research-labeled product for self-use
• ☐ Licensed clinician review of my history planned or completed
• ☐ Prescription + state-licensed pharmacy pathway understood (if applicable)
• ☐ Label/pharmacy identity looks legitimate; cold-chain/shipping questions asked
• ☐ I know this is not a promise of results
• ☐ Discovery call (if used) understood as non-clinical / may-be-candidate only

Bring this list to your visit. Do not self-dose from blogs, influencers, or research-chemical storefronts.

FAQ

Is this a shopping guide for peptides or GLP-1s?

No. It is a question list for clinician visits, grounded in FDA consumer warnings. It does not endorse vendors or products.

Are compounded GLP-1 drugs FDA-approved?

No. FDA states compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.

What about products labeled “for research” or “not for human consumption”?

FDA has warned about unapproved products sold with those labels plus dosing instructions for human use, and urges consumers not to purchase them.

Does Regen Therapy MD claim I am already a candidate?

No. A discovery call is non-clinical and explores what you may be a candidate for. A physician decides only after a proper consult.

How do I talk with Regen Therapy MD?

Book online, use Contact Us, call (424) 349-6008, or email book@regentherapymd.com.

Talk with Regen Therapy MD

If you want help turning this checklist into a physician-directed conversation—not a self-selected online product—start here:

• Book: https://book.mypatientnow.com/practice/TqZLiT
• Contact: https://www.regentherapymd.com/contact-us
• Phone: (424) 349-6008
• Email: book@regentherapymd.com

Clinic: Beverly Hills — 8920 Wilshire Blvd, Suite 604

Disclaimers (footer)

Educational content only — not medical advice, not legal advice, diagnosis, or a treatment plan. Does not confirm candidacy. Individual results vary; no outcome promises. FDA-approved brand products and compounded formulations are not equivalent. Compounded drugs are not FDA-approved. Not a shopping guide; no vendor endorsement. No dosing or protocols. Telehealth/shipping only where licensed; no nationwide-service claim. Discovery call = non-clinical / may-be-candidate framing. No fabricated testimonials. Prefer cited FDA sources for regulatory statements; PMID 35441470 is cited only for published withdrawal evidence context.

Sources

1. U.S. FDA. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
2. U.S. FDA. Compounding and the FDA: Questions and Answers.
3. U.S. FDA. BeSafeRx: Know Your Online Pharmacy (consumer online-pharmacy safety resources referenced from FDA’s unapproved GLP-1 page).
4. Wilding JPH, et al. STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID 35441470 (withdrawal evidence context only—not a personal forecast).